An Introduction to the (epi)genomics of chronic lymphocytic leukemia
An Introduction to the (epi)genomics of chronic lymphocytic leukemia
Chronic Lymphocytic Leukaemia (CLL) is a B-cell malignancy and the most prevalent leukaemia in the Western world, most prevalent in elderly individuals. The disease exhibits vast clinical heterogeneity, ranging from a benign disease for many decades, to one requiring immediate treatment. With the application of modern genomic technologies, we now have a detailed view of the genomic architecture of the CLL genome. This includes a detailed catalogue of the genes targeted by copy number changes and mutations in the disease, as well as their clinical impact. Additionally, we have an expanding understanding of the epigenetic profile of the disease, that gives fundamental insights into the original transforming cell, and the regulatory networks contributing to the disease. This information has considerable clinical implications, improving diagnosis, prognostication and helping to guide therapeutic interventions with greater accuracy.
Makewita, Lara
c8cbdea1-b800-41b3-b0d9-ad1a8e6e8e90
Strefford, Jonathan
3782b392-f080-42bf-bdca-8aa5d6ca532f
Makewita, Lara
c8cbdea1-b800-41b3-b0d9-ad1a8e6e8e90
Strefford, Jonathan
3782b392-f080-42bf-bdca-8aa5d6ca532f
Makewita, Lara and Strefford, Jonathan
(2019)
An Introduction to the (epi)genomics of chronic lymphocytic leukemia.
In,
eLS.
(Essential Life Sciences)
Chichester.
John Wiley & Sons.
(doi:10.1002/9780470015902.a0028437).
Record type:
Book Section
Abstract
Chronic Lymphocytic Leukaemia (CLL) is a B-cell malignancy and the most prevalent leukaemia in the Western world, most prevalent in elderly individuals. The disease exhibits vast clinical heterogeneity, ranging from a benign disease for many decades, to one requiring immediate treatment. With the application of modern genomic technologies, we now have a detailed view of the genomic architecture of the CLL genome. This includes a detailed catalogue of the genes targeted by copy number changes and mutations in the disease, as well as their clinical impact. Additionally, we have an expanding understanding of the epigenetic profile of the disease, that gives fundamental insights into the original transforming cell, and the regulatory networks contributing to the disease. This information has considerable clinical implications, improving diagnosis, prognostication and helping to guide therapeutic interventions with greater accuracy.
Text
2019_Makewita_Strefford_CLL_Review_eLS
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 11 December 2018
e-pub ahead of print date: 20 March 2019
Identifiers
Local EPrints ID: 429546
URI: http://eprints.soton.ac.uk/id/eprint/429546
PURE UUID: 15f8e369-85df-4623-91e6-0ae98456d47c
Catalogue record
Date deposited: 29 Mar 2019 17:30
Last modified: 16 Mar 2024 03:40
Export record
Altmetrics
Contributors
Author:
Lara Makewita
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics